Literature DB >> 31287729

Proton MR spectroscopy and the detection of malignancy in ovarian masses.

Sahar Mahmoud Mansour1, Mohammed Mohammed Mohammed Gomma2, Peter Nashaat Shafik2.   

Abstract

OBJECTIVE: To assess the impact of MR spectroscopy (MRS) on the detection of malignancy in ovarian masses.
METHODS: This prospective work included 230 females that had 245 adnexal/ovarian masses. Tumours were spotted by preliminary pelvic ultrasound. Masses assessed by MRI, multi- or single-voxel spectroscopy. Patients' spectra were assessed for peaks of lactate (Lac, 1.31 ppm), lipid (Lip, 1.33 ppm), N-acetyl aspartate (2.0 ppm), acetone (A, 2.05 ppm), choline (Cho, 3.23 ppm) and creatinine (Cr, 3.4 ppm) and the mean values of the (Cho/Cr) ratios were performed by a semi-quantitative approach. The operative pathology served as the standard of reference.
RESULTS: Cho peak twofold higher than the average noise level was detected in 72% of the malignant and only 5.4% of the benign masses with an accuracy of 83%. Adding lactate to the choline enhanced the accuracy to 93%. The mean Cho/Cr ratios of the malignant ovarian masses (2.8) were significantly higher than that of the benign ones (1.2) . We used a receiver operating characteristic curve to determine the best cut-off value (1.7) for the mean Cho/Cr ratio to discriminate malignancy with sensitivity: 81.2%, specificity: 93.3 %, positive-predictive value: 92.9 %, negative-predictive value: 82.4% and accuracy: 87.1%.
CONCLUSION: The simultaneous presence of choline and lactate peaks in MRS examination of the ovarian masses minimizes the overlap between benign and malignant categories. N-acetyl aspartate and acetone are the metabolites for diagnosing complex cystic masses as benign teratoma, endomterioma and tubo- ovarian abscess. ADVANCES IN KNOWLEDGE: MRS is a non-contrast based and fast MR sequence that gives an idea about tissue components could be used to improve the sensitivity and the accuracy of detecting malignancy in ovarian masses.

Entities:  

Mesh:

Year:  2019        PMID: 31287729      PMCID: PMC6732908          DOI: 10.1259/bjr.20190134

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  19 in total

1.  Characterization of adnexal mass lesions on MR imaging.

Authors:  S A Aslam Sohaib; Ahju Sahdev; Philippe Van Trappen; Ian J Jacobs; Rodney H Reznek
Journal:  AJR Am J Roentgenol       Date:  2003-05       Impact factor: 3.959

2.  MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors.

Authors:  Feng Hua Ma; Jin Wei Qiang; Song Qi Cai; Shu Hui Zhao; Guo Fu Zhang; Ya Min Rao
Journal:  AJR Am J Roentgenol       Date:  2015-06       Impact factor: 3.959

3.  Role of proton MR spectroscopy in the differentiation of borderline from malignant epithelial ovarian tumors: A preliminary study.

Authors:  Feng Hua Ma; Yong Ai Li; Jia Liu; Hai Ming Li; Guo Fu Zhang; Jin Wei Qiang
Journal:  J Magn Reson Imaging       Date:  2018-10-24       Impact factor: 4.813

4.  MRI for the diagnosis of ultrasonographically indeterminate pelvic masses.

Authors:  Saleha Anwar; Bushra Rehan; Gulzar Hameed
Journal:  J Pak Med Assoc       Date:  2014-02       Impact factor: 0.781

5.  In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy.

Authors:  Anastassia Esseridou; Giovanni Di Leo; Luca M Sconfienza; Valentina Caldiera; Francesco Raspagliesi; Barbara Grijuela; Francesco Hanozet; Franca Podo; Francesco Sardanelli
Journal:  Invest Radiol       Date:  2011-06       Impact factor: 6.016

6.  High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid.

Authors:  E A Boss; S H Moolenaar; L F Massuger; H Boonstra; U F Engelke; J G de Jong; R A Wevers
Journal:  NMR Biomed       Date:  2000-08       Impact factor: 4.044

7.  Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy.

Authors:  T Okada; M Harada; K Matsuzaki; H Nishitani; T Aono
Journal:  J Magn Reson Imaging       Date:  2001-06       Impact factor: 4.813

8.  Ex vivo 1H and 31P magnetic resonance spectroscopy as a means for tumor characterization in ovarian cancer patients.

Authors:  Yoram Abramov; Shani Carmi; Shaoul O Anteby; Israel Ringel
Journal:  Oncol Rep       Date:  2012-10-05       Impact factor: 3.906

9.  Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla.

Authors:  Peter Stanwell; Peter Russell; Jonathan Carter; Selvan Pather; Sebastian Heintze; Carolyn Mountford
Journal:  Invest Radiol       Date:  2008-10       Impact factor: 6.016

Review 10.  New MR techniques in gynecologic cancer.

Authors:  Jennie C Wakefield; Kate Downey; Stavroula Kyriazi; Nandita M deSouza
Journal:  AJR Am J Roentgenol       Date:  2013-02       Impact factor: 3.959

View more
  2 in total

Review 1.  The use of hyperpolarised 13C-MRI in clinical body imaging to probe cancer metabolism.

Authors:  Ramona Woitek; Ferdia A Gallagher
Journal:  Br J Cancer       Date:  2021-01-28       Impact factor: 7.640

2.  In vivo detection of dysregulated choline metabolism in paclitaxel-resistant ovarian cancers with proton magnetic resonance spectroscopy.

Authors:  Jing Lu; Ying Li; Yong Ai Li; Li Wang; An Rong Zeng; Xiao Liang Ma; Jin Wei Qiang
Journal:  J Transl Med       Date:  2022-02-15       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.